2030年までのアジア太平洋乳がん治療薬市場予測 - 地域分析 - 薬物療法別 [標的薬物療法 (アベマシクリブ、アドトラスツズマブ エムタンシン、パルボシクリブ、トラスツズマブ、その他の標的薬物療法)、ホルモン薬物療法 (選択的エストロゲン受容体調節剤、アロマターゼ阻害剤)] 、選択的エストロゲン受容体ダウンレギュレーター）、化学療法、免疫療法/生物学的療法]、乳がんの種類（ホルモン受容体、HER2+、トリプルネガティブ乳がん）、流通チャネル（病院の薬局、ドラッグストアと小売薬局、オンライン薬局） ）
いくつかの診断およびスクリーニング プログラムの発売がアジア太平洋地域の乳がん治療市場を促進
個別化医療、免疫療法、併用療法、ドラッグデリバリーシステム、リキッドバイオプシー、AI、患者中心のアプローチが乳がん治療の将来を形作ると期待されています。これらの傾向は、治療結果を改善し、副作用を軽減し、乳がん患者の全体的な生活の質を向上させることを目的としています。
病気の早期発見は、患者の転帰と生存率の向上に大きな役割を果たします。さまざまな組織や医療提供者が、治療可能な初期段階で乳がんを検出するためのスクリーニング プログラムを実施しています。世界保健機関は、2013 年 2 月に、2040 年までに 250 万人を乳がんから救うという目標を達成するための計画として、新しい世界乳がんイニシアチブ枠組みを発表しました。これを達成するために、新しい枠組みは世界対がんデーに先立って発表されました。このキャンペーンでは、乳がんの早期発見、迅速な診断、徹底的な管理のための健康増進の 3 本柱に従うよう各国に呼びかけています。これらのプログラムには、乳がんの異常や兆候を特定するためのマンモグラフィー、臨床乳房検査、自己乳房検査が含まれることがよくあります。これらのプログラムの実施により、乳がん症例の認識と早期発見が高まり、その結果、効果的な治療法に対する需要が高まりました。
さらに、診断技術における多くの進歩が世界中で目撃されています。国立医学図書館は、予後を高めるには早期発見と正確な診断が不可欠であると述べています。乳がんの評価では、デジタル マンモグラフィー (DM)、デジタル乳房トモシンセシス (DBT)、磁気共鳴画像法 (MRI)、超音波 (US)、核医学処置などの放射線画像診断法が頻繁に利用されます。組織病理学 (HP) は、がんの存在を判定するためのゴールドスタンダードです。さらに、人工知能 (AI) テクノロジーを使用して医療画像を定量的に描写することは、乳がんのセグメンテーション、診断、予後を改善する大きな可能性を秘めています。これらのテクノロジーは、医療提供者が腫瘍の範囲と特徴を特定するのに役立ち、個別の治療計画を開発できるようになります。したがって、診断およびスクリーニングプログラムの開始は、診断技術の進歩と相まって、アジア太平洋地域の乳がん治療市場の成長に貢献しています。
アジア太平洋地域の乳がん治療薬市場の概要
アジア太平洋地域の乳がん治療薬市場は、中国、日本、インド、韓国、オーストラリア、およびその他のアジア太平洋地域に分割されています。市場の成長は、個別化医療、免疫療法、併用療法、薬物送達システムの進歩に加え、女性の乳がん負担の増大などの要因に起因すると考えられています。
中国の乳がん治療薬市場は、乳がんの罹患率の上昇、高齢化人口の増加、ライフスタイルの変化などにより、今後数年間で大幅な成長を遂げると予測されています。 2023年4月14日に発表されたCDC統計によると、2020年に世界で新たに診断された症例の24％、がん関連死亡者数の30％を中国が占めた。過去30年間で、乳がんの年齢標準化罹患率は17.07歳から上昇した。 1990 年の 10 万人あたりの割合は、2019 年の 10 万人あたり 35.61 人でした。治療選択肢の進歩は、中国における乳がん治療薬の需要を促進する上で重要な役割を果たしています。
また、日本の女性の10人に1人は、いつか乳がんに罹患します。 10月のピンクリボンキャンペーンなどにより、日本人の間でこの病気に対する意識が高まり、セルフチェックなどの早期発見方法を活用すれば生存率は90％以上に高まるという。しかし、典型的なリスク変数の特定は遅れています。したがって、日本の乳がん治療薬市場は、人口の高齢化、治療の選択肢、政府の取り組みと政策、高額な医療費、意識の高まり、技術の進歩により、大幅に成長すると予想されています。
アジア太平洋地域の乳がん治療薬市場の収益と2030年までの予測（百万米ドル）
アジア太平洋地域の乳がん治療薬市場のセグメンテーション
アジア太平洋地域の乳がん治療薬市場は細分化されています薬物療法、乳がんの種類、流通チャネルに基づいて決定されます。
アジア太平洋地域の乳がん治療薬市場は、薬物療法に基づいて、標的薬物療法、ホルモン薬物療法、化学療法、免疫療法/生物学的療法に分類されます。分子標的薬治療セグメントは、2022年にはより大きなシェアを保持しました。分子標的薬治療セグメントは、2022年にはより大きなシェアを保持しました。分子標的薬治療セグメントは、アベマシクリブ、アドトラスツズマブ エムタンシン、パルボシクリブ、トラスツズマブ、およびその他の標的薬物療法にさらにサブセグメント化されています。さらに、ホルモン薬物療法セグメントは、選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、選択的エストロゲン受容体ダウンレギュレーターに分類されます。
乳がんの種類に関して、アジア太平洋地域の乳がん治療薬市場は、ホルモン受容体、HER2+、トリプルネガティブ乳がんに分類されます。 2022 年には、ホルモン受容体セグメントがより大きなシェアを占めました。
アジア太平洋地域の乳がん治療薬市場は、流通チャネルごとに、病院薬局、ドラッグストアおよび小売薬局、オンライン薬局に分類されます。 2022 年には、病院薬局セグメントがより大きなシェアを占めました。
アジア太平洋地域の乳がん治療薬市場は、国ごとにオーストラリア、中国、インド、日本、韓国、およびその他のアジア太平洋地域に分類されます。 2022 年のアジア太平洋地域の乳がん治療薬市場は中国が独占しました。
イーライリリー社、エーザイ株式会社、ノバルティス AG、アストラゼネカ Plc、ファイザー社、ギリアド サイエンシズ社、メルク社、テバ ファーマシューティカル インダストリーズ社、 Amgen Inc および Amgen Inc は、アジア太平洋地域の乳がん治療市場で事業を展開する大手企業の一部です。
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - Asia Pacific Market Analysis
5.1 Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Breast Cancer Therapeutics Market -Country Analysis
9.1 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Asia Pacific Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 Asia Pacific Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
9.1.3.1 China
9.1.3.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Japan
9.1.3.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 India
9.1.3.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Australia
9.1.3.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 South Korea
9.1.3.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Asia Pacific
9.1.3.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation
Table 2. Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. China Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. China Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. China Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. China Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. China Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Japan Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Japan Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. India Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. India Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. India Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. India Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. India Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 23. Australia Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. South Korea Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. South Korea Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 36. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution